Acorda Therapeutics Inc  

(Public, NASDAQ:ACOR)   Watch this stock  
Find more results for ACOR
36.22
+0.87 (2.46%)
After Hours: 36.22 0.00 (0.00%)
Feb 10, 4:25PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 35.37 - 37.65
52 week 25.50 - 43.63
Open 35.66
Vol / Avg. 1.08M/732,279.00
Mkt cap 1.55B
P/E 754.27
Div/yield     -
EPS 0.05
Shares 43.16M
Beta 1.64
Inst. own 111%
Feb 23, 2016
Acorda Therapeutics Inc at RBC Capital Markets Healthcare Conference - 3:05PM EST - Add to calendar
Feb 11, 2016
Acorda Therapeutics Inc at Leerink Partners Global Healthcare Conference - 3:05PM EST - Add to calendar
Feb 11, 2016
Q4 2015 Acorda Therapeutics Inc Earnings Release - 9:30AM EST - Add to calendar
Feb 11, 2016
Q4 2015 Acorda Therapeutics Inc Earnings Call - 8:30AM EST - Add to calendar
Jan 19, 2016
Acorda Therapeutics Inc to Acquire Biotie Therapies Conference Call - Webcast
Jan 11, 2016
Acorda Therapeutics Inc at JPMorgan Healthcare Conference
Dec 8, 2015
Acorda Therapeutics Inc at Oppenheimer Healthcare Conference - Webcast
Nov 19, 2015
Acorda Therapeutics Inc at Jefferies Autumn Global Healthcare Conference
Nov 18, 2015
Acorda Therapeutics Inc at Stifel Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 2.66% 4.40%
Operating margin 17.33% 9.06%
EBITD margin - 12.92%
Return on average assets 1.44% 2.09%
Return on average equity 2.79% 3.60%
Employees 489 -
CDP Score - -

Address

420 Saw Mill River Rd
ARDSLEY, NY 10502-2605
United States - Map
+1-914-3474300 (Phone)
+1-914-3474560 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Acorda Therapeutics, Inc. is a biopharmaceutical company engaged in the identification, development and commercialization of therapies that restore neurological function and treat patients with neurological disorders. The Company’s markets three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10milligrams, a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company is also developing a number of clinical and preclinical stage therapies for the treatment of a range of disorders, including chronic post-stroke walking deficits (PSWD), Parkinson’s disease, epilepsy, heart failure, MS, and spinal cord injury.

Officers and directors

Ron Cohen M.D. President,Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Michael W. Rogers Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
Andrew R. Blight Ph.D. Chief Scientific Officer
Age: 64
Bio & Compensation  - Reuters
Jane Wasman J.D. President - International, General Counsel, Corporate Secretary
Age: 58
Bio & Compensation  - Reuters
Andrew Asa Hindman Chief Business Development Officer
Age: 42
Bio & Compensation  - Reuters
David W Lawrence Chief - Business Operations
Age: 57
Bio & Compensation  - Reuters
Lauren M. Sabella Chief Commercial Officer
Age: 54
Bio & Compensation  - Reuters
Barry E. Greene Independent Director
Age: 51
Bio & Compensation  - Reuters
Peder K. Jensen M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
John P. Kelley Independent Director
Age: 62
Bio & Compensation  - Reuters